Opinion|Videos|June 3, 2024
Alzheimer’s Disease Pipeline
Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.
Advertisement
Video content above is prompted by the following question:
- Please provide an overview of robust Alzheimer’s pipeline and many disease modifying therapies under investigation.
- Discuss novel and emerging treatments that are most advanced in clinical studies or have promising data:
- Valiltramiprosate (ALZ-801,inhibits amyloid oligomer formation, oral)
- ALN-APP (RNAi therapeutic)
- Blarcamesine (sigma-1 and muscarinic receptors ligand)
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
3
Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy
4
Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP
5